MedPath

Efficacy of Alpha-Blocker Add-on Therapy to Tadarafil Treated Men with Lower Urinary Tract Sympto

Not Applicable
Conditions
benign prostatic hypertrophy
Registration Number
JPRN-UMIN000015311
Lead Sponsor
Department of Urology, Keio University School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
Male
Target Recruitment
58
Inclusion Criteria

Not provided

Exclusion Criteria

1. Prostate cancer 2. Episode of urinary retention within 6 months 3. Residual urine volume >150ml 4. Urinary tract infection, neurogenic bladder

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
OABSS, IPSS and urodynamic parameter such as Qmax and residual volue of urine.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath